Efficacy of oral combination antiviral therapy in genotype 4 hepatitis C infection and the importance of rapid virological response

Basit Öğe Kaydı
dc.contributor.authorAltinkaya, Engin
dc.contributor.authorAktas, Ahmet
dc.date.accessioned2024-10-26T18:05:39Z
dc.date.available2024-10-26T18:05:39Z
dc.date.issued2022
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: To evaluate the efficacy and safety of ombitasvir (OMV), paritaprevir (PTV), ritonavir (r), ribavirin (RBV) (OMV/PTVr + RBV), ledipasvir (LDV) and sofosbuvir (SOF) therapies in genotype 4 (GT4) patients, and to determine if the rapid virological response (RVR) observed at 4th week of therapy has a role in predicting sustainability of the response at week 12 (SVR12) post-therapy. Methods: The investigation included 71 subjects with diagnosis of Hepatitis C (HCV) GT4. Some of the patients (40/71) were treated using combination of OMV (25 mg/day), PTV (150 mg/day), ritonavir (r) (100 mg/day), while the others (31/71) were treated using combination of LDV (90 mg/day) and SOF (400 mg/day). Body weight-based RBV was added to both treatment regimens, and the treatments given for a total of 84 days. Viral levels in the patients were evaluated after the 4th and 12th week of drug administration, and at 12 weeks post-administration. Results: The SVR12 responses of the patients on the basis of sub-groups, were 97.5 % for OMV/PTVr + RBV, 96.8 % for LDV/SOF + RBV (p = 0.6); 91.3 % for cirrhotic, 100 % for non-cirrhotic (p = 0.1); 100 % in untreated, and 95.5 % for treated (p = 0.33). While there were numerical differences, these were not statistically significant. The SVR12 response was 100 % in patients with RVR response, and 87.5 % for patients without RVR response (p < 0.05). When the patients' aspartate transaminase (AST), alanine transaminase (ALT), platelet (PLT), albumin, creatinine, prothrombin time (PT) and fib4 values before and after treatment were compared, significant difference were observed for all variables (p < 0.01), except for PT (p = 0.3). there were no dangerous adverse events such as decompensation or death, aside from mild fatigue, with incidence of 19 %. Conclusion: RVR response after OMV/PTVr + RBV and LDV/SOF + RBV treatments show that the treatments can be used safely and effectively in patients with HCV genotype 4. Moreover, RVR might be a suitable determinant of SVR12 response.
dc.identifier.doi10.4314/tjpr.v21i1.23
dc.identifier.endpage157
dc.identifier.issn1596-5996
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85124628305
dc.identifier.scopusqualityQ3
dc.identifier.startpage151
dc.identifier.urihttps://doi.org/10.4314/tjpr.v21i1.23
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29119
dc.identifier.volume21
dc.identifier.wosWOS:000752051200008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherPharmacotherapy Group
dc.relation.ispartofTropical Journal of Pharmaceutical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGenotype 4 patients
dc.subjectombitasvir
dc.subjectparitaprevir
dc.subjectritonavir
dc.subjectribavirin
dc.subjectledipasvir
dc.subjectsofosbuvir
dc.subjectefficacy
dc.titleEfficacy of oral combination antiviral therapy in genotype 4 hepatitis C infection and the importance of rapid virological response
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu